ClinicalTrials.gg
Not yet recruitingNCT05489185Updated May 17, 2023

Clinical Trial to Assess the Efficacy of Tranexamic Acid in Reducing Blood Loss in Hip Fracture Patients.

A Phase 4 interventional study of Tranexamic acid and Physiologic saline in Hip Fractures, sponsored by Biogipuzkoa Health Research Institute. Not yet recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by Biogipuzkoa Health Research Institute · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
644
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing Tranexamic Acid in Hip Fractures — 2 open to participants now, 3 under way, none of them phase 3. Tranexamic Acid · Hip Fractures.

Planned enrollment
Largest of 21
644 · median 120
Started
2023
the only one that year
Phase 4
9 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
1 of 22
Biogipuzkoa Health Research Institute

Among the 22 studies testing Tranexamic Acid in Hip Fractures, this one has the largest planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2023, is one of 9 in phase 4, and was the 21st registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

2 of the 22 studies testing Tranexamic Acid in Hip Fractures are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing Tranexamic Acid in Hip Fractures, or all of them as a file.
02

Study summary

Hip fracture in elderly patients is a pathology with a high economic and health impact on the patient himself and on the National Health System, especially considering the significant aging of the population of the Basque Country. Despite advances, hip fracture remains in the clinical groups with the highest in-hospital mortality. Hip fracture is associated with numerous adverse events and high mortality.

Numerous antifibrinolytics, such as tranexamic acid (TXA), have been used to limit bleeding in orthopedic surgery and thus prevent the need for blood transfusion. Numerous studies have shown that the use of tranexamic acid does not increase the risk of thrombosis.

It is proposed to carry out clinical research with drugs without commercial interest. A randomized, double-blind clinical trial to assess the efficacy of tranexamic acid in reducing blood loss in elderly patients with hip fracture.

Read the detailed description

Prevention and treatment of bleeding due to general or local fibrinolysis

03

Conditions studied

  • Hip Fractures

Keywords

  • Hip Fracture
  • Blood loss
  • tranexamic acid
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over or equal to 65 years of age, of both sexes, who are going to be operated on for a hip fracture
  • Accept participation in the study ( that will be signed by the patient or family member/legal representative depending on the patient's degree of autonomy).

Exclusion criteria

Exclusion Criteria:

  • Under treatment with another experimental drug (who is not participating in another clinical trial with an experimental drug).
  • The refusal of the patient or their relatives/legal representative to participate in the study.
  • Known allergy to TXA ( Hipersensivity to TXA o to any of the ).
  • Patients with a history of seizures.
  • Patients with severe renal and hepatic insufficiency.
  • Patients with venous thrombosis.
  • Patients with active concomitant bleeding of renal origin.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
644 participants (estimated)

Study arms

  • Placebo comparator
    Extracapsular fracture with intravenous contraindication (control).

    Physiological saline

    Other: Physiologic saline

  • Experimental
    Extracapsular fracture with intravenous contraindication (experimental).

    Amchafibrin

    Drug: Tranexamic acid

  • Placebo comparator
    Extracapsular fracture without intravenous contraindication (control).

    Physiological saline

    Other: Physiologic saline

  • Experimental
    Extracapsular fracture without intravenous contraindication (experimental).

    Amchafibrin

    Drug: Tranexamic acid

  • Placebo comparator
    Intracapsular fracture with intravenous contraindication (control).

    Physiological saline

    Other: Physiologic saline

  • Experimental
    Intracapsular fracture with intravenous contraindication (experimental).

    Amchafibrin

    Drug: Tranexamic acid

  • Active comparator
    Intracapsular fracture without intravenous contraindication (control).

    Physiological saline

    Other: Physiologic saline

  • Experimental
    Intracapsular fracture without intravenous contraindication (experimental).

    Amchafibrin

    Drug: Tranexamic acid

Interventions

  • Intravenous or topical administration

  • OtherPhysiologic saline

    Placebo

06

What researchers measure

Primary outcomes

  1. Blood transfusion

    Transfusion rate from patient admission to hospital discharge.

    Time frame: From date of randomization until the date of hospital discharge, it is estimated to be day 3 post - operation.

Secondary outcomes

  1. Total blood loss

    Time frame: From date of randomization until the date of hospital discharge, it is estimated to be day 3 post - operation.

  2. Adverse events

    Time frame: 3,6,9 and 12 months

  3. Days at hospital

    Time frame: From date of randomization until the date of hospital discharge, it is estimated to be day 3 post - operation.

07

Study locations

1 site
  • Asociación Instituto Biodonostia
    San Sebastián, Guipuzcoa 20014, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2023; primary completion for Jun 2024, 12 months later.

Of 33 non-industry phase 4 interventional studies under Hip Fractures, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 12 months is below that.

Counting every sponsor, half of 33 studies reached it within 25 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 5, 2022
StartEst.
May 30, 2023
Primary completionEst.
Jun 1, 2024
CompletionEst.
Jun 1, 2025
Last update
May 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05489185
Lead sponsor
Biogipuzkoa Health Research Institute
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
May 30, 2023 (estimated)
Primary completion
Jun 1, 2024 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
May 17, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion